460 Stock Overview An investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Sihuan Pharmaceutical Holdings Group Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Sihuan Pharmaceutical Holdings Group Historical stock prices Current Share Price HK$0.66 52 Week High HK$1.02 52 Week Low HK$0.49 Beta 0.58 1 Month Change -5.71% 3 Month Change 22.22% 1 Year Change 6.45% 3 Year Change -53.85% 5 Year Change -31.25% Change since IPO -89.00%
Recent News & Updates
Upcoming dividend of HK$0.021 per share Sep 20
First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023) Sep 02
Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024 Aug 30
Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Aug 20
Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration Jun 26
New major risk - Revenue and earnings growth Jun 14 See more updates
Upcoming dividend of HK$0.021 per share Sep 20
First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023) Sep 02
Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024 Aug 30
Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Aug 20
Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration Jun 26
New major risk - Revenue and earnings growth Jun 14
Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA Jun 13
Now 21% undervalued after recent price drop May 24
Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022) Apr 28
Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024 Mar 29
Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022) Mar 29
Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets Jan 23
Now 20% undervalued after recent price drop Jan 17
Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes Jan 08
National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical Oct 26
First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022) Aug 31
Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023 Aug 18
Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial Jul 06
Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China Jul 04
Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration Jun 02
Upcoming dividend of HK$0.037 per share at 9.7% yield May 30
Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021) Mar 26
Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022 Jan 21
Less than half of directors are independent Nov 16
Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes Oct 15
Upcoming dividend of HK$0.037 per share Sep 23 Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022
First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021) Aug 31
Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022 Aug 19
Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022 Aug 17
Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China Jul 28
Upcoming dividend of HK$0.13 per share May 19
Investor sentiment deteriorated over the past week May 07
Less than half of directors are independent Apr 27
Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica Apr 19
Now 20% undervalued Apr 08
Full year 2021 earnings released: EPS: CN¥0.044 (vs CN¥0.054 in FY 2020) Mar 31
Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022 Mar 31 Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022
Investor sentiment deteriorated over the past week Mar 16
Now 25% undervalued after recent price drop Mar 15
Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails Mar 10
Investor sentiment improved over the past week Feb 16
National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd Jan 28
Now 22% undervalued after recent price drop Jan 26 Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel
Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval Dec 22
Investor sentiment deteriorated over the past week Sep 29
First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020) Sep 04
Non-Executive Director Jin-ha Kim has left the company Aug 07
Investor sentiment deteriorated over the past week Jul 27
Investor sentiment deteriorated over the past week Jul 08
Upcoming dividend of HK$0.016 per share Jun 29
Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection Jun 17
Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021 May 29
Investor sentiment improved over the past week May 27
Investor sentiment improved over the past week Apr 16
Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends Mar 25
Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019) Mar 24
Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021 Mar 12
New 90-day high: HK$2.68 Feb 17
Sihuan Pharmaceutical Holdings Group Ltd. Announces Octreotide Acetate Injection (1Ml: 0.05Mg and 1Ml: 0.1Mg) of the Group has Obtained the Notice of Approval of Supplemental Applications on Pharmaceutical Products Issued by the National Medical Products Administration of the People's Republic of China Feb 09
Sihuan Pharmaceutical Holdings Group Ltd. Announces Selection of its Pantoprazole Sodium Injection (Panzuoer® 40mg per unit) and Ibuprofen Injection (Falanfen® 4ml: 0.4g, Tenaan® 8ml: 0.8g) in the Fourth Batch of National Drug Centralized Procurement Feb 05 Sihuan Pharmaceutical Holdings Group Ltd. Announces Cinepazide Maleate Injection Obtain Approval from the National Medical Products Administration
New 90-day high: HK$1.32 Jan 20
Upcoming Dividend of HK$0.035 Per Share Sep 22
Sihuan Pharmaceutical Holdings Group Ltd.(SEHK:460) dropped from FTSE All-World Index (USD) Sep 21
First half earnings released Sep 14
Deputy General Manager recently bought HK$19m worth of stock Sep 03
Earnings released Aug 26
New 90-day high - HK$1.03 Aug 21
Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2020 Results on Aug 25, 2020 Aug 14 Shareholder Returns 460 HK Pharmaceuticals HK Market 7D -2.9% -3.3% -2.2% 1Y 6.5% -2.4% 18.3%
See full shareholder returns
Return vs Market: 460 underperformed the Hong Kong Market which returned 18.3% over the past year.
Price Volatility Is 460's price volatile compared to industry and market? 460 volatility 460 Average Weekly Movement 12.2% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.9% 10% most volatile stocks in HK Market 18.7% 10% least volatile stocks in HK Market 4.1%
Stable Share Price: 460 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 460's weekly volatility (12%) has been stable over the past year.
About the Company Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China. The company operates through three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. It offers filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care, and others, as well as non- or minimally invasive medical aesthetics comprehensive solutions.
Show more Sihuan Pharmaceutical Holdings Group Ltd. Fundamentals Summary How do Sihuan Pharmaceutical Holdings Group's earnings and revenue compare to its market cap? 460 fundamental statistics Market cap HK$6.14b Earnings (TTM ) -HK$40.25m Revenue (TTM ) HK$1.87b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 460 income statement (TTM ) Revenue CN¥1.75b Cost of Revenue CN¥598.10m Gross Profit CN¥1.16b Other Expenses CN¥1.19b Earnings -CN¥37.80m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.0041 Gross Margin 65.91% Net Profit Margin -2.15% Debt/Equity Ratio 21.4%
How did 460 perform over the long term?
See historical performance and comparison Dividends
6.1% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 17:56 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sihuan Pharmaceutical Holdings Group Ltd. is covered by 24 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Shaojing Tong BofA Global Research Harry He China Galaxy International Securities (Hong Kong) Sze Chuen Tam Core Pacific -Yamaichi International (H.K.) Limited
Show 21 more analysts 
